Role_of_the_Host_Full-width

The IO Revolution, Part 2 of 4: The Role of the Host in the Cancer Immunity Cycle

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these sources of inter-patient heterogeneity has the potential to influence the...

/ January 12, 2017
FGJJJ1 T lymphocytes and cancer cell. Coloured scanning electron micrograph (SEM) of T lymphocyte cells (smaller round cells) attached

Presidents, Rock Stars and Companion Diagnostics: 2016 Review of Immunotherapy

President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer detect the cancer. In 2016, high-profile success stories, the inclusion...

/ January 7, 2017
ash2016_outervenue

ASH 2016: Subtyping in Diffuse Large B-Cell Lymphoma

NanoString at ASH 2016. We attended the annual meeting of the American Society of Hematology (ASH) in San Diego. The convention center was abuzz with scientists sharing their research on the clinical utility of stem cells, the mechanics of the...

/ January 4, 2017
cancer-immunogram

The Cancer Immunogram: A Picture of Personalized Medicine

What do we already know about tumor-immune system interactions, and how can this information be used to help guide us toward the best therapeutic choice? That is exactly the question that a group of researchers from the Netherlands Cancer Institute,...

/ December 27, 2016
sitc_event_entrance_lg

SITC 2016 Recap

Looking beyond anti-PD1/PDL1 with combination therapy and gene signature testing

/ November 21, 2016